352 related articles for article (PubMed ID: 8921576)
1. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic risk factors and oral contraception.
Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
[TBL] [Abstract][Full Text] [Related]
3. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
4. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
6. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
7. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.
Manten B; Westendorp RG; Koster T; Reitsma PH; Rosendaal FR
Thromb Haemost; 1996 Oct; 76(4):510-3. PubMed ID: 8902987
[TBL] [Abstract][Full Text] [Related]
8. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].
Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H
Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622
[TBL] [Abstract][Full Text] [Related]
9. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Martinelli I; Cattaneo M; Panzeri D; Mannucci PM
Thromb Haemost; 1997 Mar; 77(3):440-3. PubMed ID: 9065990
[TBL] [Abstract][Full Text] [Related]
10. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
12. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Bennet L; Odeberg H
J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
[TBL] [Abstract][Full Text] [Related]
13. [Resistance to activated protein C. The most common cause of familial thrombophilia].
Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Svensson PJ; Zöller B; Dahlbäck B
Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
[TBL] [Abstract][Full Text] [Related]
16. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Svensson PJ; Benoni G; Fredin H; Björgell O; Nilsson P; Hedlund U; Nylander G; Bergqvist D; Dahlbäck B
Thromb Haemost; 1997 Sep; 78(3):993-6. PubMed ID: 9308742
[TBL] [Abstract][Full Text] [Related]
17. Resistance to activated protein C as a basis for venous thrombosis.
Svensson PJ; Dahlbäck B
N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317
[TBL] [Abstract][Full Text] [Related]
18. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
[TBL] [Abstract][Full Text] [Related]
19. Factor V gene mutation is a risk factor for cerebral venous thrombosis.
Martinelli I; Landi G; Merati G; Cella R; Tosetto A; Mannucci PM
Thromb Haemost; 1996 Mar; 75(3):393-4. PubMed ID: 8701395
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
Weitz IC; Israel VK; Liebman HA
Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
